
Brief Brain Stimulation Effective for Depression in Parkinson's Disease
Magnetic seizure therapy (MST) demonstrated non-inferiority to ultra-brief electroconvulsive therapy (ECT) for depression, with fewer cognitive adverse effects.

AD Biomarkers Linked to Worse Cognition in Midlife Adults
Elevated Alzheimer's disease biomarkers in midlife adults are associated with poorer cognitive performance, indicating preclinical disease progression.

Preventing 45 Percent Of Dementia Cases
The Lancet Commission 2024 estimates 45% of dementia is preventable. SPRINT-MIND showed 19% MCI reduction from intensive blood pressure control. FINGER showed 25% better cognitive scores with multi-domain lifestyle intervention. ACHIEVE showed 48% slowing i...

Targeting Tau Inflammation And Alzheimer's Metabolism
Amyloid clearance is only one part of the Alzheimer's story. Why tau remains the closer correlate of cognitive decline, what the TREM2 biology tells us about microglia, what the GLP-1 signal means, and how platform trials are moving toward multi-target comb...

Why New Alzheimer's Drugs Make Brains Bleed?
ARIA — amyloid-related imaging abnormalities — affects up to 24% of patients on anti-amyloid therapy. APOE4 genotyping, MRI monitoring protocols, severity-graded management, and the anticoagulation dilemma: a practical guide to navigating the risk.

The Amyloid Hypothesis, Finally Validated?
After two decades of high-profile failures, lecanemab and donanemab have produced the first positive phase 3 trials in Alzheimer's disease. We examine the CLARITY-AD and TRAILBLAZER-ALZ 2 data, the clinical meaningfulness debate, and what the approvals actu...

CGRP Monoclonal Antibodies for Migraine Linked to Fracture Risk
New data indicate CGRP monoclonal antibodies, used for migraine prevention, may be associated with an increased risk of bone fractures. Clinicians should consider this risk.

Reassuring Data for High-Efficacy MS Meds in Pregnancy
New data provide reassurance regarding the use of high-efficacy multiple sclerosis therapies during pregnancy, addressing a significant clinical dilemma.

Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.

CGRP Inhibitors for Migraine: CV Safety Data Limited in High-Risk Patients
CGRP-targeted therapies are effective for migraine prevention, but cardiovascular safety data is limited in patients with established vascular disease.